primary human dermal microvascular lecs (Lonza)
Structured Review

Primary Human Dermal Microvascular Lecs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+human+dermal+microvascular+lecs/human+dermal+lecs/pmc08087398-205-0-10
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Mitochondrial respiration controls the Prox1-Vegfr3 feedback loop during lymphatic endothelial cell fate specification and maintenance"
Article Title: Mitochondrial respiration controls the Prox1-Vegfr3 feedback loop during lymphatic endothelial cell fate specification and maintenance
Journal: Science Advances
doi: 10.1126/sciadv.abe7359
Figure Legend Snippet: ( A and B ) Transverse sections at the level of the anterior CV show that expression of Vegfr3 is severely reduced in differentiating Prox1-expressing LECs outside the CV. Similarly, other LEC markers such as Pdpn ( C and D ) and Lyve1 ( E and F ) are also down-regulated, whereas expression of the pan-endothelial markers VEcad ( G and H ) and CD31 ( I and J ) is normal. White box insets correspond to higher magnification of the dotted box region in each panel. Arrows indicate dorsal (D) and lateral (L) orientations. Mean fluorescence intensity of each staining was quantified and shown as percentage of mean of control group in ( K ) and ( L ). Each data point represents a biological replicate. All results are presented as means ± SEM and analyzed by multiple t test. Scale bar, 50 μm ( n = 6).
Techniques Used: Expressing, Fluorescence, Staining, Control
Figure Legend Snippet: ( A to J ) At E12.5, expression of Prox1 still remains in the mutant embryos; however, expression of most other LEC markers is barely detected or is severely down-regulated. Expression of the pan-endothelial marker CD31seems normal. White arrows in control embryo (E) point to the dermal lymphatic vasculature; mutant LECs fail to sprout from the lymph sacs such that lymph sacs (LS) become abnormally enlarged and mutant embryos lack dermal lymphatics. White box insets correspond to higher magnifications of the regions inside the dotted boxes in each panel. Mean fluorescence intensity of each staining was quantified and shown as percentage of mean of control group in ( K ). Each data point represents a biological replicate. Area of the CV and lymph sac was quantified and shown as fold change of lymph sac area compared to CV in each genotype ( L ). All results are presented as means ± SEM and analyzed by multiple t test for (K) and two-tailed Student’s t test for (L). Scale bar, 50 μm ( n = 3 to 8).
Techniques Used: Expressing, Mutagenesis, Marker, Control, Fluorescence, Staining, Two Tailed Test
Figure Legend Snippet: ( A and B ) At E11.5, QPC f/f ;PdpnGFPCre LECs show severely reduced Vegfr3 levels, but similar to controls, Prox1 + LECs do not coexpress BEC markers such as CD34 ( n = 3). ( C and D ) At around E12.5, Vegfr3 expression becomes undetectable in mutant LECs and Prox1 + (low) LECs abnormally up-regulate the expression of CD34, an indication that they are losing LEC fate and regaining BEC fate. White arrows indicate Prox1 + CD34 + LECs. Blood cells are abnormally seen inside the mutant lymph sacs (D), most likely a consequence of defective lymphovenous valves. White box insets correspond to higher magnification of the regions in dotted boxes in each panel. CD34 + Prox1 + cells were quantified and shown as percentage of Prox1 + in each group ( E ). Each data point represents a biological replicate. All results are presented as means ± SEM and analyzed by two-tailed Student’s t test. Scale bar, 50 μm ( n = 6).
Techniques Used: Expressing, Mutagenesis, Two Tailed Test
Figure Legend Snippet: ( A ) Antimycin A (Anti) treatment reduces Prox1 ( n = 9), Vegfr3 ( n = 9), and Nrp2 ( n = 5) mRNA levels but not those of VEcad ( n = 3). ( B ) Myxothiazol (Myx) treatment also reduces Prox1 ( n = 4), Vegfr3 ( n = 6), and Nrp2 ( n = 3) mRNA levels but not those of VEcad ( n = 3). ( C ) Representative Western blot shows that antimycin A and myxothiazol treatment reduces VEGFR3 ( n = 6) and PROX1 ( n = 6) levels but not those of VECAD ( n = 5 to 6). ( D ) Quantification of the densitometry of each protein normalized to GAPDH and shown as fold change compared to controls. Each data point represents a biological replicate. All results are presented as means ± SEM and analyzed by multiple t test in (A) and (B) or two-way analysis of variance (ANOVA) in (D). ( E and F ) RNA-seq of LECs treated with vehicle or antimycin A shows that expression of most LEC genes in the dataset is reduced, while almost half of the BEC genes are up-regulated, including Nrp1 and ICAM1 ( n = 3).
Techniques Used: Western Blot, RNA Sequencing, Expressing
Figure Legend Snippet: Antimycin A inhibits OCR ( A ), NAD + /NADH ratio ( B ), and cell proliferation ( C ) in LECs transduced with EV-GFP, while AOX rescues OCR ( n = 3 to 4) (A), NAD + /NADH ratio ( n = 3) (B), and cell proliferation ( n = 3) (C) in the presence of antimycin A. AOX also rescued the Vegfr3 , Prox1 , and Nrp2 levels in the presence of antimycin A ( D ) ( n = 5 to 6). Each data point represents a biological replicate. All results are presented as means ± SEM and analyzed by one-way ANOVA for (A) to (C) or two-way ANOVA for (D).
Techniques Used: Transduction
Figure Legend Snippet: Mitochondrial complex III inhibition with antimycin A alters TCA cycle metabolites ( A ) and 2HG levels ( B ). Values are normalized to mean of control group. ( C ) ChIP-seq analysis of H3K27ac, H3K4me3, and H3K4me1 histone modifications in LEC cultures treated with vehicle control (Ctrl) or antimycin A (Anti) for 48 hours. Track examples for LEC-specific genes ( Prox1 and Vegfr3 ) and BEC genes ( Nrp1 and ICAM1 ) are shown. Antimycin A–treated LECs show a marked reduction in the H3K4me3 and H3K27ac signal at the Vegfr3 locus and a reduction in H3K4me3 in the Prox1 locus, while H3K27ac peaks are increased in the Nrp1 and ICAM1 locus. ( D ) ChIP-seq analysis of the same modifications in (C) in LECs and BECs reveals that H3K27ac and H3K4me3 peaks are elevated in the Prox1 and Vegfr3 loci in LECs, whereas those of Nrp1 and ICAM1 are reduced in LECs and BECs. Scale bar, 5 kb. Each data point represents a biological replicate. All results are presented as means ± SEM and analyzed by multiple t test or two-tailed Student’s t test.
Techniques Used: Inhibition, Control, ChIP-sequencing, Two Tailed Test
Figure Legend Snippet: Venous ECs (VECs) inside the CV are glycolytic. Starting at around E9.5, CoupTFII and Sox18 induce Prox1 expression in some VECs inside the CV to give rise to Prox1 + LEC progenitors. Specification of LEC fate, LEC budding, and maintenance of LEC fate is regulated by a Prox1-Vegfr3 feedback loop. Prox1 also regulates CPT1a, which, in turn, increases FAO in LECs. FAO-derived acetyl-CoA promotes histone acetylation by the histone acetyltransferase P300 and Prox1 complex at lymphangiogenic genes such as Vegfr3 . In addition, ketone body oxidation mediated by 3-oxoacid-CoA-transferase-1 (OXCT1) also generates acetyl-CoA, regulates TCA cycle metabolites and aspartate and dNTP levels, and is required for LEC proliferation. We demonstrate that mitochondrial respiratory chain is required for LEC fate maintenance. When complex III is blocked, mutant embryos lack LECs as a consequence of loss of Vegfr3 expression and LEC fate. Mitochondrial respiration is required for nucleotide synthesis and the maintenance of H3K4me3 and H3K27ac histone modifications at the Vegfr3 and Prox1 promoters. Blockage of mitochondrial respiration reduced Vegfr3 and disrupted the Vegfr3-Prox1 feedback loop.
Techniques Used: Expressing, Derivative Assay, Mutagenesis
